Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TYSABRI pregnancy exposure registry

Next Previous
X
Search
Trial Profile

TYSABRI pregnancy exposure registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TPER; TYGRIS
  • Sponsors Biogen Idec

    • Most Recent Events

    • 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Oct 2010 Preliminary results were presented in an abstarct at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2010 According to an abstract of preliminary results, presented at the 26th Congress of ECTRIMS, as of 23 February 2010, 198 patients were registered prospectively to TPER, with 148 outcomes reported.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top